Omid Farokhzad, MD, director of the Laboratory of Nanomedicine and Biomaterials at BWH and associate professor in the Department of Anesthesiology, was recently named one of two 2013 Laureates of the RUSNANOPRIZE, the largest international nanotechnology prize, for his work in advancing nanoparticle technologies. Farokhzad is being recognized in the field of Nanomaterials and Surface Modification for his role in the innovation, development and industrialization of nanoparticle technologies for medical applications.
The award is also given to a company that has achieved significant commercial success due to implementation of the winning research. Given this, the RUSNANOPRIZE also recognizes BIND Therapeutics, cofounded by Farokhzad, for successfully applying his winning research into industrial production. BIND's lead drug candidate is BIND-014, which is a targeted and controlled release nanoparticle in phase II clinical trials for treatment of lung and prostate cancers. BIND-014 is the first targeted and controlled release nanoparticle technology to reach human clinical trial.
Read more at this BWH page.